Becaplermin
| Clinical data | |
|---|---|
| Trade names | Regranex |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a699049 |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration |
Topical |
| Identifiers | |
| CAS Number | 165101-51-9  |
| ATC code | A01AD08 (WHO) , D03AX06 |
| DrugBank | DB00102 |
| UNII | 1B56C968OA |
| ChEMBL | CHEMBL1201556  |
| (what is this?) (verify) |
|
Becaplermin (brand name Regranex) is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. [1] It is also known as "platelet-derived growth factor BB".[2]
Medical uses
The drug is used for the treatment of diabetic foot ulcers.[3] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[4] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[5]
The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. [6] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [7]
Contraindications
Becaplermin must not be used at the site of a skin cancer.[8]
Adverse effects
The most common side effects in clinical studies were erythematous rashes.[8]
A boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[9] Regranex should be used with caution in patients with known malignancy.[10]
References
- ↑ http://www.regranex.com/patient/pdf/PI_full_version.pdf.
- ↑ becaplermin at the US National Library of Medicine Medical Subject Headings (MeSH)
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21:822-827.
- ↑ Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg. 2002;19:483-491. Persson U, Willis M, Odegaard K, Apelqvist J. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health. 2000;3 Suppl 1:39-46.
- ↑ http://www.regranex.com/patient/pdf/PI_full_version.pdf
- ↑ Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
- ↑ 8.0 8.1 FDA Professional Drug Information for Regranex.
- ↑ Medscape Article
- ↑ http://www.regranex.com/patient/pdf/PI_full_version.pdf
